



METHODS AND KITS FOR PREDICTING LUNG CANCER PROGNOSIS

PI : Prof. Sung-Liang Yu

Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University

Experience:

Position

Professor and Director, Department of Clinical Laboratory Sciences and Medical Biotechnology, NTU

Joint Professor, Graduate School of Advanced Technology, NTU

Joint Professor, Department of Pathology and Graduate Institute of Pathology, NTU

Joint Professor, Institute of Medical Device and Imaging, NTU

Professor and Principal Investigator, Centers for Genomics and Precision Medicine, NTU

Education

Ph.D.; Ins. Microbiology and Immunology, Natl. Yang-Ming University

Market Needs:

According to Cancer Registry Annual Report, 2021 Taiwan of the Health Promotion Administration, 35.3% of the newly diagnosed lung cancer patients are patients with early-stage resectable lung cancer, a total of 7,512 people (stage 0 to stage IIIA), of which 94% (7,070 people) of patients who underwent curative surgery are the target audiences of this invention. 85.1% of newly diagnosed lung cancer cases belong to stage 0 to 1 since July 1, 2022, lung cancer screening has been included as the 5th cancer screening in Taiwan. An estimated demand will be 17,169 people per year.

Our Technology:

By using a combination of protein biomarkers and a recurrence risk score, the method of the present invention provides a valuable tool for monitoring and managing lung cancer patients, enabling timely intervention and personalized treatment strategies.

Strength:

- (1) Utilized the universal clinical laboratory testing method that can be directly adapted by medical centers.
- (2) Utilized novel and validated biomarkers to accurately predict the risk of postoperative recurrence in patients.

Competing Products: None.

Intellectual Properties: None.

Contact (do not need to fill out):

Center for Industry-Academia Collaboration, NTU

Tel: 02-3366-9945, E-mail: ordiac@ntu.edu.tw